Cảm biến thảm siêu âm là gì? Tìm hiểu tất tần tật về cảm biến này
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.
Boehringer Ingelheim strengthens footprint in Swiss biotech innovation hub.
Basel, Switzerland, Thursday, 03.04.2025 – Today NBE Therapeutics (NBE) a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to innovation in oncology and strengthens its footprint in Switzerland’s biotech ecosystem. NBE Therapeutics, a Swiss biotech founded in 2012 that became part of Boehringer Ingelheim in 2020, plays a pivotal role in the company’s oncology research strategy. The new facility will serve as a leading research center for advancing antibody-drug conjugates (ADC) research and development, supporting Boehringer Ingelheim’s commitment to developing transformative cancer therapies to improve patients’ lives globally.
Advancing ADC research with investment in Swiss NBE Therapeutics site
This investment in NBE’s Basel site is a significant step toward Boehringer Ingelheim’s goal of transforming cancer care. It bolsters our robust oncology pipeline and adds on top of a recent license agreement with Synaffix B.V., Amsterdam, expanding NBE‘s ADC portfolio and the recent opening of a new facility at our oncology research site in Vienna, Austria. The new research facility will contribute to building a broad pipeline of ADCs, addressing novel tumor target space to develop next-generation cancer treatments.
NBE Therapeutics focuses on developing next-generation ADCs, a targeted approach that delivers cancer-fighting agents directly to tumor cells while limiting effects on healthy tissue. ADCs combine the specificity of antibodies with the therapeutic activity of cytotoxics, offering a promising option for cancer treatment to improve the quality of life for patients.
'This investment in a new, cutting-edge research center underscores our strong commitment to deliver breakthrough innovation to people living with cancer,' said Jean Engela, CEO at NBE Therapeutics. 'We are confident that this state-of-the-art building will enable our team of scientists to accelerate the development of next-generation ADCs, ultimately impacting the lives of patients battling cancer.'
The new facility represents an additional commitment of CHF 27 million in ADC R&D over several years. It will provide a sophisticated research environment to accelerate the development of innovative ADC therapies, while fostering synergies through access to a broad pool of scientists and experts within the global Boehringer Ingelheim oncology network.
A commitment to innovation and sustainability
“Switzerland offers an unparalleled biotech ecosystem. By strengthening our presence here, we are reinforcing our commitment to advancing innovative cancer treatments,” said Karl Penz, CFO of the Innovation Unit at Boehringer Ingelheim and Chairperson of the NBE Therapeutics Board of Directors.
Kaspar Sutter, Head of Department of Economic, Social and Environmental Affairs of the Canton of Basel-Stadt; Member of the Government said: “As the Government of Basel-Stadt we want to provide a good environment for companies to prosper, particularly in the life sciences field. The development of NBE Therapeutics is a success story and it has been a privilege to accompany and support NBE Therapeutics on this journey from the very beginning, starting at the Tech Park Basel. We very much appreciate this significant investment by NBE Therapeutics and the strong commitment of Boehringer Ingelheim to the Basel Area.”
The new R&D center meets the highest Swiss sustainability standards and has been awarded the DGNB Certificate Gold by the Schweizer Gesellschaft für Nachhaltige Immobilienwirtschaft (SGNI). This certification is based on criteria developed by the Deutsche Gesellschaft für Nachhaltiges Bauen (DGNB). Featuring energy-efficient design and responsibly sourced materials, it provides 1,826 m2 of laboratories and office space, enabling seamless collaboration with the extensive global network of Boehringer Ingelheim. The building will serve as an inspiring workplace for a team of approximately 50 scientists, in addition to various supporting functions, including HR, administration and management.
Boehringer Ingelheim footprint in Switzerland
Boehringer Ingelheim has an established presence in Switzerland and collaborates with several other biotech companies, including T3 Pharmaceuticals and Sabia Animal Health. Unlike traditional acquisitions, Boehringer Ingelheim maintains the agile structure and entrepreneurial spirit of these biotech companies, while providing them with access to additional resources, expertise, and a broad network of Boehringer scientists. This approach fosters synergies and enables these companies to thrive within Boehringer Ingelheim’s global ecosystem, while contributing to the company’s commitment to improving patients’ lives through innovation.
###
About NBE Therapeutics
NBE Therapeutics, founded in 2012 and acquired by Boehringer Ingelheim in 2020, headquartered in Basel, Switzerland, is a renowned biotechnology company at the forefront of developing next-generation antibody drug conjugate (ADC) products for cancer treatment. Committed to scientific excellence and innovation, NBE Therapeutics is dedicated to revolutionizing the field of oncology therapeutics by providing precise and effective treatment options. Leveraging cutting-edge, in-house developed technologies, NBE Therapeutics has successfully established a groundbreaking platform for antibody-drug conjugates (ADCs), specifically designed to target solid tumors. For more information about NBE Therapeutics visit the website www.nbe-therapeutics.com. [/b]
[b]Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.


TIN LIÊN QUAN
THỦ THUẬT HAY
Hướng dẫn setup màn hình nối tiếp Daisy Chain thông qua cổng Thunderbolt™ 3
Để sử dụng Daisy Chain cho kết nối đa màn hình, bạn chỉ cần sử dụng một đầu ra Thunderbolt ™ 3 của cổng I / O trên máy tính, kết nối với đầu vào Thunderbolt ™ 3 của màn hình đầu tiên và một Thunderbolt ™ 3 đầu tiên màn
Bản cập nhật iOS 10.3.2 cải thiện hiệu năng, tăng cường bảo mật
Rạng sáng hôm nay, Apple đã chính thức phát hành iOS 10.3.2 mới nhất cho iPhone, iPad và iPod touch. Bản cập nhật lần này tập trung chủ yếu vào và lỗi và cải thiện hiệu suất cũng như tăng cường bảo mật cho các thiết bị.
Quét virus trực tuyến với Phrozen VirusTotal Uploader
Virustotal hiện nay đã cho phép người dùng tải các tập tin nghi ngờ có dung lượng 64 MB lên hệ thống để kiểm tra độ an toàn trước khi cài đặt, nhưng với công cụ hỗ trợ Virustotal Uploader thì chỉ cho phép giới hạn cao
2 câu hỏi phỏng vấn này sẽ tiết lộ ứng viên nào có chỉ số trí tuệ cảm xúc cao
Hãy luôn cẩn thận với những đòn tâm lý của nhà tuyển dụng.
Cách tắt lớp phủ màn hình Samsung, Sony, Xiaomi, Huawei
Lớp phủ màn hình thường có ở những điện thoại Android 6.0 trở lên. Lớp phủ có nhiệm vụ sắp xếp các ứng dụng chạy nền trên điện thoại của bạn theo thứ tự ưu tiên.
ĐÁNH GIÁ NHANH
Đánh giá HTC U: Ảo tưởng về giá hay thực sự cao cấp?
Từ bao giờ mà việc định giá sản phẩm cao hay thấp quyết định sự thành công hay thất bại của một doanh nghiệp?
So sánh iPhone 13 Pro Max và iPhone 12 Pro Max: Có nên nâng cấp không?
iPhone 13 Pro Max sở hữu ngoại hình tương tự iPhone 12 Pro Max khiến không ít người phân vân khi lựa chọn. Trong bài viết dưới đây mình sẽ đi so sánh iPhone 13 Pro Max và iPhone 12 Pro Max để tìm ra sự khác biệt giữa
Đánh giá Mercedes A-Class 2019 về nội ngoại thất và giá bán
Về ngoại thất tổng thể, Mercedes A-Class 2019 thế hệ mới đại diện cho một bước đi tiếp theo trong triết lý thiết kế Sensual Purity của Mercedes-Benz. Những đường nét mạnh mẽ của mẫu xe thế hệ thứ ba đã biến mất, thế